Skip to Content

Gongwin Biopharm Holdings Co Ltd 6617

Morningstar Rating
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

6617 is trading at a 28% discount.
Price
TWD 181.13
Fair Value
TWD 598.65
Uncertainty
Extreme
1-Star Price
TWD 834.28
5-Star Price
TWD 65.18
Economic Moat
Dqjz
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 6617 is a good fit for your portfolio.

Trading Information

Previous Close Price
Day Range
52-Week Range
Bid/Ask
/
Market Cap
Volume/Avg
/

Key Statistics

Price/Earnings (Normalized)
Price/Sales
1,095.74
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Gongwin Biopharm Holdings Co Ltd is a Taiwanese biotech and pharmaceutical company engaged in research and development of anti-cancer drugs. The company develops products related to central lung serious tracheal obstruction, primary liver cancer, malignant pleural effusion, and tracheal adenoid cystic carcinoma.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
27

Comparables

Valuation

Metric
6617
6541
02181
Price/Earnings (Normalized)
Price/Book Value
15.687.9112.21
Price/Sales
1,095.74101.7119.24
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
6617
6541
02181
Quick Ratio
9.711.080.69
Current Ratio
9.911.661.08
Interest Coverage
−21.66−36.74−20.87
Quick Ratio
6617
6541
02181

Profitability

Metric
6617
6541
02181
Return on Assets (Normalized)
−6.36%−55.13%−20.43%
Return on Equity (Normalized)
−7.40%−141.14%−79.65%
Return on Invested Capital (Normalized)
−9.25%−57.48%−38.37%
Return on Assets
6617
6541
02181
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRVjrrnrlwpjZbg$554.7 Bil
VRTX
Vertex Pharmaceuticals IncSmhxhwylPncwdxc$102.7 Bil
REGN
Regeneron Pharmaceuticals IncGpjjcssSbzjkkj$97.8 Bil
MRNA
Moderna IncWvgcsbqdXwdxv$41.3 Bil
ARGX
argenx SE ADRZxrhcbvFkvtm$22.3 Bil
BNTX
BioNTech SE ADRFmpfyxdskPlc$21.0 Bil
ALNY
Alnylam Pharmaceuticals IncTjspkxvhMvrtfkk$18.2 Bil
BMRN
Biomarin Pharmaceutical IncKlyrrhrZhdhxdy$15.4 Bil
RPRX
Royalty Pharma PLC Class AYzdrhmpmFmblx$12.5 Bil
INCY
Incyte CorpBkryksqXmmwsg$11.6 Bil

Sponsor Center